Functional production of human antibody by the filamentous fungus Aspergillus oryzae

Fungal biology and biotechnology
Hung Hiep HuynhJun-ichi Maruyama

Abstract

Monoclonal antibodies (mAbs) as biopharmaceuticals take a pivotal role in the current therapeutic applications. Generally mammalian cell lines, such as those derived from Chinese hamster ovaries (CHO), are used to produce the recombinant antibody. However, there are still concerns about the high cost and the risk of pathogenic contamination when using mammalian cells. Aspergillus oryzae, a filamentous fungus recognized as a GRAS (Generally Regarded As Safe) organism, has an ability to secrete a large amount of proteins into the culture supernatant, and thus the fungus has been used as one of the cost-effective microbial hosts for heterologous protein production. Pursuing this strategy the human anti-TNFα antibody adalimumab, one of the world's best-selling antibodies for the treatment of immune-mediated inflammatory diseases including rheumatoid arthritis, was chosen to produce the full length of mAbs by A. oryzae. Generally, N-glycosylation of the antibody affects immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) via binding to the Fc receptor (FcγR) on immune cells. The CRISPR/Cas9 system was used to first delete the Aooch1 gene encoding a key enzyme for the hyper-mannosylation process in ...Continue Reading

References

Sep 19, 2002·Advances in Applied Microbiology·Katsuhiko Kitamoto
Sep 19, 2002·Advances in Applied Microbiology·Masayuki Machida
Apr 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Byung-Kwon ChoiTillman U Gerngross
May 7, 2004·Applied and Environmental Microbiology·Michael WardHuaming Wang
Dec 24, 2005·Nature·Masayuki MachidaHisashi Kikuchi
Jan 24, 2006·Nature Biotechnology·Huijuan LiTillman U Gerngross
Mar 30, 2006·Biotechnology and Bioengineering·Brigitte GasserDiethard Mattanovich
Oct 18, 2006·FEMS Yeast Research·Kousuke KurodaYoshifumi Jigami
Nov 23, 2006·Biotechnology Letters·Brigitte Gasser, Diethard Mattanovich
Dec 1, 2006·The Journal of Biological Chemistry·Amita Datta-MannanVictor J Wroblewski
May 16, 2007·The Journal of Investigative Dermatology. Symposium Proceedings·Tadahiko KohnoJames S Louie
Nov 6, 2007·Advances in Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Jan 10, 2009·Nature Protocols·Pieter P JacobsNico Callewaert
May 23, 2009·British Journal of Pharmacology·Patrick ChamesDaniel Baty
Jun 30, 2010·Applied Microbiology and Biotechnology·Karen De PourcqNico Callewaert
Aug 17, 2010·Journal of Industrial Microbiology & Biotechnology·Gavin C BarnardPiotr Bobrowicz
Jan 5, 2012·Microbial Cell Factories·Giusy Manuela AdamoMarina Lotti
Oct 16, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Inbal Sela-CulangYanay Ofran
Jan 5, 2013·Journal of Hematology & Oncology·James D MellorAlexander Dobrovic
Jan 18, 2013·Molecular & Cellular Proteomics : MCP·Gerhild ZaunerManfred Wuhrer
Mar 20, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anja LuxFalk Nimmerjahn
Aug 3, 2013·Frontiers in Immunology·André FrenzelThomas Schirrmann
Apr 8, 2015·Applied Microbiology and Biotechnology·David ReinhartRenate Kunert
Aug 9, 2015·Proceedings of the National Academy of Sciences of the United States of America·Chin-Wei LinChi-Huey Wong
Mar 5, 2016·Applied Microbiology and Biotechnology·Renate Kunert, David Reinhart
May 25, 2016·Microbial Cell Factories·Jorg C de RuijterAlexander D Frey
Nov 30, 2016·World Journal of Gastroenterology : WJG·Ulrike BillmeierRaja Atreya
Jan 28, 2017·Scientific Reports·Michiru NishitaYasuhiro Minami
Mar 31, 2017·Journal of Bioscience and Bioengineering·Takeshi SuzukiYasunori Chiba
Jun 29, 2017·International Immunology·Masato KiyoshiJose M M Caaveiro
Oct 28, 2017·Frontiers in Immunology·Katerina T XenakiPaul M P van Bergen En Henegouwen
Sep 22, 2018·Reumatologia·Piotr WilandJulia Feldman
Dec 17, 2018·Current Opinion in Biotechnology·Linde Van LanduytNico Callewaert
Feb 26, 2019·Molecular Biotechnology·Roghayyeh BaghbanMaryam Aria

❮ Previous
Next ❯

Citations

Mar 10, 2021·Bioscience, Biotechnology, and Biochemistry·Yujiro Higuchi

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
PCR
size-exclusion chromatography
genetic modifications
ELISA
electrophoresis
size-fractionation

Software Mentioned

Humira
pisCIIA

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.